Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. David Goodman discusses the gaps in ADHD treatment.
Lisdexamfetamine dimesylate (Vyvanse) is one of the more interesting treatments for attention deficit/ hyperactivity disorder (ADHD), according to at least 1 presenter during the annual Neuroscience Education Institute (NEI) Max! Virtual meeting.
In an interview with HCPLive®, David W. Goodman, MD, FAPA, assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine, shared his thoughts on the benefits of Lisdexamfetamine dimesylate.
Goodman explained that the medication is the same no matter what delivery method, which means it is less abusable for users. The treatment also has a long-acting aspect to it that is beneficial for patients.
While it remains a go-to treatment for ADHD, Goodman explained it is often because of insurance companies preferences that it does not always get prescribed to patients due to cost concerns.
Goodman also discussed some gaps in ADHD, including the fact that the majority of ADHD medications are stimulant treatments. He explained the aim in research should be to develop some non-stimulant options as stand-alone or combination therapies that can last longer durations than the current stable of treatments.
Goodman presented 5 different sessions during the virtual meeting on a number of topics related to ADHD treatment.